Johnson & Johnson

The company has committed to donate up to 500,000 doses of an investigational Janssen vaccine regimen to help protect citizens of the Democratic Republic of the Congo—the site of the world’s second largest outbreak of the disease.

Check out this infographic breakdown of the company’s third-quarter performance, with key highlights from its consumer, pharmaceutical and medical devices businesses.

The company just released its inaugural Diversity & Inclusion Impact Review. We take a look inside its pages to see how the company’s striving every day to build a culture of belonging.

Our Chief Historian celebrates Edith Von Kuster’s groundbreaking role and how it set the tone for company culture in the century-plus to come.

As the IAS Conference on HIV Science kicks off in Mexico City, we explain how an investigational HIV vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson works—and how researchers hope to help change lives around the world with it.

Announced ahead of the International AIDS Society Conference on HIV Science in Mexico City, the new study will evaluate an investigational vaccine regimen in eight countries around the world for its ability to protect people from HIV infection.

Not all companies have a Chief Historian. Then again, not all companies have such a long, rich heritage of innovation. Margaret Gurowitz explains the highlights—and delights—of her unique job.

For Pride Month, Johnson & Johnson Executive Vice President Ashley McEvoy shares how the company stands behind its LGBTQIA+ employees—and why a strong culture of diversity and inclusion is crucial to successfully finding solutions for the world’s greatest healthcare problems.

As Memorial Day approaches, we’re honoring the life of the famous poet and service member, known for his iconic “Trees” poem, who was the son of the company’s first Scientific Director—and a writer for Johnson & Johnson.

A study of women, by women. We’re talking about the Imbokodo trial, which is evaluating an investigational HIV vaccine in sub-Saharan Africa. As the study hits a key milestone, we sat down with South African physician and scientist Glenda Gray, who’s at the helm of the groundbreaking trial.